Docoh
Loading...

NAVB Navidea Biopharmaceuticals

Navidea Biopharmaceuticals, Inc. engages in the development and commercialization of precision immunodiagnostic agents and immunotherapeutic. It operates through the following segments: Diagnostics, Therapeutics, and Corporate. The company was founded in 1983 and is headquartered in Dublin, OH.

Company profile

Ticker
NAVB
Exchange
CEO
Jed Latkin
Employees
Incorporated
Location
Fiscal year end
Former names
NEOPROBE CORP
SEC CIK
IRS number
311080091

NAVB stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

26 Mar 21
13 Apr 21
31 Dec 21
Quarter (USD)
Dec 20 Sep 20 Jun 20 Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 2.67M 2.67M 2.67M 2.67M 2.67M 2.67M
Cash burn (monthly) 350.79K (positive/no burn) 941.04K 894.72K 852.29K 681.15K
Cash used (since last report) 1.21M n/a 3.25M 3.09M 2.95M 2.35M
Cash remaining 1.46M n/a -581.36K -421.3K -274.66K 316.72K
Runway (months of cash) 4.2 n/a -0.6 -0.5 -0.3 0.5

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
29 Mar 21 Malcolm G Witter Common Stock Buy Aquire P No No 2.07 21,500 44.51K 47,000
3 Mar 21 Malcolm G Witter Common Stock Buy Aquire P No No 2.31 15,000 34.65K 25,500
2 Mar 21 Scott John K Jr. Series E Redeemable Convertible Preferred Stock Common Stock Buy Aquire P No No 100 50,000 5M 50,000
15 Feb 21 Latkin Jed Stock Option Common Stock Grant Aquire A No No 0.001 100,000 100 100,000
15 Feb 21 Joel H. Kaufman Stock Option Common Stock Grant Aquire A No No 0.001 25,000 25 25,000

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

13F holders
Current Prev Q Change
Total holders 0 0
Opened positions 0 0
Closed positions 0 0
Increased positions 0 0
Reduced positions 0 0
13F shares
Current Prev Q Change
Total value 0 0
Total shares 0 0
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Largest transactions
Shares Bought/sold Change
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. freshman Avg
New words: accredited, Actinium, Adaptimmune, adjudicate, aim, alpha, anticancer, article, ASR, aTyr, banker, BCF, Bellicum, Brexit, British, Calithera, CDC, Checkpoint, ChemoCentryx, Cidara, comment, CytomX, dba, Dean, devastating, dissolution, Distinguishing, docketed, Draximage, ELDA, empowering, EPS, EULAR, factor, Fate, forgiven, France, GeoVax, Germany, Goldman, hard, Heron, honesty, Indenture, inspired, Irish, Joel, Jubilant, Judge, Kaufman, Kibble, Kingdom, labor, Latin, Lineage, Magistrate, Malcolm, mandatorily, Marker, Mastiff, memorandum, mezzanine, mitigate, MOU, multiplying, Neoleukin, Neuroscience, ninety, Northwest, Northwestern, Official, OncoSec, passion, payroll, PDL, perfected, persistence, Phio, PPP, Prentice, proinflammatory, Prothena, Radiopharma, reproducible, SBA, Selecta, show, signal, Stanford, strive, synergized, syngeneic, tenant, thrive, timeline, TNF, TRA, UK, unconditional, unexpectedly, USI, virtual, webcast, Wharton, Witter, workplace, worse, Zealand, Ziopharm
Removed: AA, accessible, AD, affinity, affirmative, Affordable, alternatively, Alzheimer, amyloid, announcement, applying, attributed, autoimmune, bore, brain, budgetary, chosen, classically, cognitive, collateralized, comparator, compounding, CRC, CROI, cured, deadline, declined, dementia, departure, deplete, diagnosing, directionally, discontinued, discounted, diversion, doubt, dramatic, employing, exclusively, exempt, extinguishment, fluid, frozen, hierarchy, hinder, homeland, hurt, identical, incurrence, ineligible, infrequently, instituted, invoke, juncture, labeled, leverage, liver, living, lowest, MCI, metastatic, Miami, microgram, mild, minimal, modulate, mortality, NCI, necessarily, neurological, neurology, Obama, observable, overhaul, paying, peripheral, phenotype, possession, prepayment, pressure, quantify, quantitative, quoted, RDD, realignment, recording, reducing, relation, rental, retrospective, risen, safely, shift, simultaneously, slowly, specificity, stayed, stopped, studied, sublicensed, suggest, Summit, suspected, top, topical, transparency, treating, unadjusted, unavailable, undertaken, unexpired, unobservable, unrealized, unrestricted